NIH launches phase 3 investigational trials for pair of monoclonal antibody therapies for COVID-19

Dec 18, 2020 - 02:36 PM
NIH-cancer-deaths

The National Institutes of Health yesterday announced enrollment in phase 3 of the clinical trial of two disparate therapies. This trial is specifically looking at the safety and effectiveness of the therapeutics in people hospitalized with moderate COVID-19 symptoms.

The two approaches being tested are the use of VIR-7831, a monoclonal antibody developed through a partnership between GlaxoSmithKline and Vir Biotechnology, Inc., and a combination of neutralizing monoclonal antibodies, BRII-196 and BRII-198, that are manufactured by Brii Biosciences.

Initially, approximately 450 people will be enrolled, with a third of participants receiving a placebo, a third receiving VIR-7831 and a third getting the combination of Brii therapeutics. It the trials appear successful, an additional 700 people hospitalized with COVID-19 will be enrolled. 

Related News Articles

Headline
View the AHA's latest United Against the Flu toolkit celebrating fall
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
CDC recommends two doses of COVID-19 vaccine for older individuals, lowers pneumococcal vaccine age 
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
CDC reminds hospital and health system workers to protect themselves, patients during respiratory virus season
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Chair File: The Best Defense Against Flu and COVID-19
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
Survey: Less than 20% of U.S. adults concerned for themselves or family receiving infection ahead of respiratory virus season
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
FDA authorizes combination tests for flu, COVID-19
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…